AZ-UNIVERSAL-ELECTRONICS
1.5.2020 22:17:07 CEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in universal control and sensing technologies for the smart home, has received five 2020 Red Dot Awards , one of the most prestigious international design awards, in the Product Design category. Products from UEI’s consumer brand, One For All , won four of the five awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200501005501/en/
The award-winning products were designed by UEI’s design team in the Netherlands, part of the global Designovation team which creates product designs based on user insights and innovative technology. Led by Rex Xu, Director of Design and User Experience, the team in the Netherlands works closely with UEI’s design offices in the U.S. and Hong Kong to ensure all products truly reflect global trends in design and technology.
“Winning five Red Dot Awards is a true honor and a testament to our design team’s exceptional talent,” said Xu. “Design is one of UEI’s key differentiators and we always create our designs with the user experience in mind. The team works under clear guiding principles of our successful Designovation formula which creates honest product designs based on true consumer insights applying the latest technology and design trends.”
Two of One For All’s TV stands were recognized with 2020 Red Dot Awards:
The Tripod Universal TV Stand fits televisions up to 65 inches, can swivel a true 360 degrees and blends into any corner with natural chestnut or oak wooden legs for a modern look.
The One For All Falcon Universal TV Stand supports televisions up to 70 inches and is designed to accommodate soundbars, streaming boxes and game consoles connected to the television. With its fabric skinned storage cover at the back of the television, cables are completely out of sight.
One For All also won two Red Dot awards for its market-leading digital TV antennas:
The Amplified Indoor TV Antenna features leading reception technology in a beautiful fabric skinned housing. With its homey design, it can hang on the wall, stand or lie flat while allowing for maximum channel coverage.
The darker colored Amplified Indoor TV Antenna offers a stylish look and unique signal level indicator that blends into the fabric housing. This ensures optimal signal and maximum number of available channels.
The fifth Red Dot Award is for UEI’s Kita premium Android TV voice remote control specifically designed for service providers with advanced video services that want a simplified user experience. In addition to supporting voice control and dedicated streaming app keys, this remote control features adaptive control which interacts with the television and only shows users the keys they need. It uses rechargeable technology in a slim housing, saving multiple batteries over the life of the product.
For more information about how to purchase these award-winning products, contact info@uei.com .
In 2019 One For All won Red Dot Awards for its Amplified Indoor Ball Design Antenna and One For All FLUX Gas Spring TV Wall Mount. With origins dating back to 1955, the Red Dot is established internationally as one of the most sought-after quality marks for outstanding design with annual competitions for Product Design, Brands and Communication, and Design Concept. Red Dot Award submissions are evaluated by a jury of independent designers, design professors and journalists.
All trademarks appearing herein are the property of their respective owners.
One For All is a registered trademark of Universal Electronics Inc.
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in universal control and sensing technologies for the smart home. The company designs, develops, manufactures and ships over 500 innovative products that are used by the world’s leading brands in the consumer electronics, subscription broadcast, security, home automation, hospitality and climate control markets. For more information, visit www.uei.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200501005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom